Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 1, 2014, Pages 50-58

  Chen, Yuhchyau ^a   Nowak, Irena ^a   Huang, Jiaoti ^b   Keng, Peter C ^a   Sun, Hongliang ^a   Xu, Haodong ^a   Wei, Gang ^a   Lee, Soo Ok ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell signaling; Erk mitogen activated protein kinases; Neuroendocrine differentiation; Non small cell lung cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CELL DIFFERENTIATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BUTADIENES; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; LEAD; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEUROSECRETORY SYSTEMS; NITRILES; PHOSPHOPYRUVATE HYDRATASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84891754004     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000034     Document Type: Article

References (41)

1. Cersosimo RJ. Lung cancer: A review. Am J Health Syst Pharm 2002;59:611-642
2. Berendsen HH, de Leij L, Poppema S, et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989;7:1614-1620
3. Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer 2003;97:2487-2497
4. Kiriakogiani-Psaropoulou P, Malamou-Mitsi V, Martinopoulou U, et al. The value of neuroendocrine markers in non-small cell lung cancer: A comparative immunohistopathologic study. Lung Cancer 1994;11:353-364
5. Carey FA, Save VE. Neuroendocrine differentiation in lung cancer. J Pathol 1997;182:9-10
6. Senden N, Linnoila I, Timmer E, et al. Neuroendocrine-specific protein (NSP)-reticulons as independent markers for non-small cell lung cancer with neuroendocrine differentiation. An in vitro histochemical study. Histochem Cell Biol 1997;108:155-165
7. Chang KT, Huang CY, Tsai CM, Chiu CH, Lok YY. Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. Am J Physiol Lung Cell Mol Physiol 2005;289:L438-L445
8. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 2005;289:L446-L453
9. Chong S, Lee KS, Chung MJ, et al. Neuroendocrine tumors of the lung; clinical, pathologic and imaging findings. Radiographic 2006;26:41-57
10. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-553
11. G azdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 1988;48:4078-4082
12. G raziano SL, Tatum A, Herndon JE II, et al. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: A Cancer and Leukemia Group B study. Lung Cancer 2001;33:115-123
13. Linnoila IR. Spectrum of neuroendocrine differentiation in lung cancer cells lines featured by cytomorphology, markers, and their corresponding tumors. J Cell Biochem Suppl 1996;24:92-106
14. Schleusener JT, Tazelaar HD, Jungs S, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 1996;77:1284-1290
15. Hiroshima K, Iyoda A, Shibuya K, et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg 2002;73:1732-1735
16. Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 2001;20:1563-1569
17. Jull BA, Plummer HK III, Schuller HM. Nicotinic receptor-mediated by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol 2001;127:707-717
18. Walker GE, Antoniono RJ, Ross HJ, et al. Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: Regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1. Oncogene 2006;25:1943-54
19. Baccarini M. Second nature: Biological functions of the Raf-12 kinase;. FEBS Lett 2005;579:3271-3277
20. Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997;14:1635-1642
21. Dhanasekaran DN, Johnson GL. MAPKs: Function, regulation, role in cancer and therapeutic targeting. Oncogene 2007;26:3097-3099
22. Kim J, Adam RM, Freeman MR. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 2002;62:1549-1554
23. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-970
24. Seger R, Ahn NG, Posada J, et al. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J Biol Chem 1992;267:14373-14381
25. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-822
26. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000;19:6594-6599
27. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009;283:125-134
28. Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007;1773:1248-1255
29. Walker GE, Antoniono RJ, Ross HJ, Paisley TE, Oh Y. Neuroendocrinelike differentiation of non-small cell lung carcinoma cells: Regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1. Oncogene 2006;25:1943-1954
30. Lin YW, Chuang SM, Yang JL. ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J Biol Chem 2003;278:21534-21541
31. Carnaghi C, Rimassa L, Garassino I, Santoro A. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. Ann Oncol 2001;12 Suppl 2:S119-S123
32. Howe MC, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 2005;46:195-201
33. Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance. Am J Surg Pathol 2007;31:26-32
34. Segawa Y, Takata S, Fujii M, et al. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol 2009;135:1055-1059
35. Nishida E, Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 1993;18:128-131
36. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007;26:3227-3239
37. G ioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-284
38. Barry OP, Mullan B, Sheehan D, et al. Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEKindependent. J Biol Chem 2001;276:15537-15546
39. Ohori M, Kinoshita T, Okubo M, et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 2005;336:357-363
40. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005;5:350-356
41. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-11858